SYNERGY™ & SYNERGY MEGATRON™

EES PtCr Coronary Stent System

SYNERGY Stent Clinical Program and Research

Addressing the full spectrum of cardiovascular disease complexity

Short DAPT SYNTAX II High Bleeding Risk Other Clinical Studies
Join our COMPLEX PCI COMMUNITY
The SYNERGY Stent design goals are to address needs surrounding complex PCI. As a result, Boston Scientific established a robust clinical trial program and is supporting investigator-sponsored research1 (ISR) that is studying the SYNERGY Stent in many different patient populations that interventional cardiologists see in their everyday practice.
 
Synergy Clinical Program
 

Consistently low sub-acute, late & very late ST in 18,000 patients across 9 studies

 ARC ST (Def) Rates for the SYNERGY™ Stent2
 SWEET RegistryFribourg ExperienceBelfast ExperienceEVOLVE II TrialEVOLVE TrialEVOLVE ChinaEVOLVE II QCA StudySCAAR Registry

BIO-RESORT

Trial

N:8206711858469420510014,9791172
Acute

1.5%

0.3%

0%

0.2%

0%

0%

0%

0.08%*

0.1%

Sub-acute

0.1%

0.3%

0%

0%

0%

0%

0%

0.02%*

0.1%

Late

0.1%

0.1%

0%

0%

0%

0%

0%

0.2%*

0.2%

Very Late  

0%

0.3%

0%

 

 

0.1%*

0.3%

Acute: ≤ 1 day; Subacute: 2 – 30 days; Late: 30 days – 1 year; Very Late: Beyond 1 year
* Cumulative adjusted ARC def ST estimated from Kaplan Meier Curve.
 

SYNERGY ™ BP Stent Ranked #1 and Promus PREMIER ™ PP Stent Ranked #2 for the lowest relative risk of Definite/Probably Stent Thrombosis

Kang Network Meta-Analysis: Relative ST risk at 1-year from 111,088 patients3
Promus PREMIER vs. comparators
Kang Network Meta-Analysis

Study Design (ST Analysis)

  • 110 prospective, randomized controlled trials included
  • 111,088 patients
  • Primary endpoint: definite or probable stent thrombosis at 1 year
Caution should be taken in interpreting study results, as some stents had limited numbers of comparisons, and some of the studies had a potential risk of bias.
*All PtCr-EES stents, also includes PROMUS Element and PROMUS Element Plus. Def/prob ST was available in 110 studies with 111,088 patients.
 

SYNERGY BP Stent showed numerically lowest ST rates compared to other DES despite being used in patients with more complex disease

SYNERGY™ Stent Safety: ST rates in real-world SCAAR registry4
ST rates in real-world SCAAR registry
 SYNERGY StentDESp
N patients

4,247

38,110

<0.01

Class B2/C Lesions

59%

54%

<0.01

LM

6.9%

6.1%

NS

CTO

4.8%

4.1%

NS

2VD

30.0%

29.4%

NS

Diabetes

23.1%

21.9%

<0.01

Prior PCI

31.2%

29.2%

<0.01

3VD

17.4%

16.6%

<0.01

Stent Diameter

2.95 mm

3.00 mm

<0.01

Stent Length

22.32 mm

20.32 mm

<0.01

A total of 7,886 of Synergy stents and 64,429 other n-DES (BioMatrix, N= 1,953; Orsiro, N= 4,946; Promus Element Plus, N= 2,543; Promus Premier, N= 20,414; Xience Xpedition, N= 7,971, Resolute/Resolute Integrity, N=19,021; Ultimaster, N= 1,156; Resolute Onyx, N= 6,425) were implanted in 42,357 procedures.
 
Optimal Healing

Optimal Healing

Advanced design for optimal healing

Button
Real-World

Real-World Studies

How design impacts economic value

Button
Top